Did you mean 1400 60 7?
Displaying drugs 2076 - 2100 of 3153 in total
Progabide
Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these...
Experimental
RU79072
Experimental
RU79073
Experimental
RU78191
Experimental
INCB7839
INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.
Investigational
R-348
Investigational
MBO7133
MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. AraC's anti-cancer activity is associated with its ability to be converted to its biologically active form, araCTP. However, araC is only slowly...
Investigational
JHU-75528 C-11
JHU-75528 C-11 is under investigation in clinical trial NCT03204305 (Brain Imaging of Cannabinoid Receptors).
Investigational
AZD7442
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that...
Investigational
ABBV-CLS-7262
Investigational
RU78783
Experimental
RU78299
Experimental
Osbond acid
Experimental
alpha-Carotene
Experimental
Olcegepant
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential...
Investigational
SNS-032
Investigational
6-Hydroxy-5-undecyl-4,7-benzothiazoledione
Experimental
Blarcamesine
Investigational
MDL72527
Experimental
FG-9041
Experimental
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Demplatin pegraglumer
Demplatin pegraglumer is under investigation in clinical trial NCT02043288 (Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer).
Investigational
RU79256
Experimental
RU78262
Experimental
RU78300
Experimental
Displaying drugs 2076 - 2100 of 3153 in total